Ajay K. Nooka
Expertise in
10
conditions

Dr. Ajay K. Nooka

Hematology Oncology
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
Offers Telehealth
26 Years of Experience
Referral may be required
Expertise in
10
conditions
Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 

Overview

Ajay Nooka is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 26 years.

Dr. Nooka is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Dr. Nooka is board certified in American Board Of Internal Medicine, 2011. He is actively involved in clinical research, co-authoring 194 peer reviewed articles and participating in 13 clinical trials.

Graduate Institution

NTR University Of Health Sciences/Andhra Medical College, 2000.0

Residency

Canton Medical Education Foundation

Specialties

Hematology Oncology

Licenses

Internal Medicine in GA

Board Certifications

American Board Of Internal Medicine, 2011

Fellowships

Winship Cancer Institute

Hospital Affiliations

Grady Memorial Hospital
Emory University Hospital Midtown
Emory University Hospital

Languages Spoken

English
Hindi
Telugu

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Emory Winship Cancer Institute
1365 Clifton Road Northeast, BldgC, Atlanta, GA 30322

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
A Phase II Study of Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: January 12, 2026
Intervention Type: Drug
Study Drugs: Elotuzumab, Pomalidomide, Dexamethasone
Study Phase: Phase 2
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5
Enrollment Status: Active_not_recruiting
Publish Date: November 06, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab
Study Phase: Phase 2
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents
Enrollment Status: Completed
Publish Date: July 12, 2024
Intervention Type: Drug
Study Drugs: Panobinostat Capsules, Bortezomib Injection, Dexamethasone Tablets
Study Phase: Phase 2
Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy
Phase II Study of Pembrolizumab as Salvage Therapy Among Multiple Myeloma Patients Progressing on CAR-T Cell Therapy
Enrollment Status: Withdrawn
Publish Date: July 03, 2024
Intervention Type: Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
A Phase I/II Single Arm Open-Label Study to Explore Safety and Clinical Activity of GSK2857916 Administered in Combination With Pembrolizumab in Subjects With Relapsed/Refractory Multiple Myeloma (DREAMM 4)
Enrollment Status: Completed
Publish Date: April 09, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
A Phase 1/2, Dose Escalation Safety and Tolerability Study of AO-176 as Monotherapy and in Combination With Bortezomib and Dexamethasone in Adults With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: August 22, 2023
Intervention Type: Drug
Study Drugs: AO-176, AO-176 + Dex, AO-176 + Dex + Bort
Study Phase: Phase 1/Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

194 Total Publications

Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.
Spatial multi-omics of multiple myeloma uncovers niche-dependent pro-myeloma and immunosuppressive signaling in the bone marrow and extramedullary lesions.
Journal: bioRxiv : the preprint server for biology
Published: April 03, 2026
Similar Doctors
Expertise in
26
conditions
Dr. Jonathon B. Cohen
Hematology Oncology
Expertise in
26
conditions
Dr. Jonathon B. Cohen
Hematology Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Jonathon Cohen is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 19 years. Dr. Cohen is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Mantle Cell Lymphoma (MCL), Non-Hodgkin Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Vitrectomy. Dr. Cohen is board certified in American Board Of Internal Medicine, 2014.

Expertise in
20
conditions
Dr. Kristie A. Blum
Hematology Oncology
Expertise in
20
conditions
Dr. Kristie A. Blum
Hematology Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-1900
Experience:
29+ years
Languages Spoken:
English
See accepted insurances

Kristie Blum is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. She has been practicing medicine for over 29 years. Dr. Blum is highly rated in 20 conditions, according to our data. Her clinical expertise encompasses Mantle Cell Lymphoma (MCL), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Blum is board certified in American Board Of Internal Medicine, 2004.

Expertise in
27
conditions
Dr. Edmund K. Waller
Hematology Oncology
Expertise in
27
conditions
Dr. Edmund K. Waller
Hematology Oncology

Emory Winship Cancer Institute

1365 Clifton Road Northeast, BldgC, 
Atlanta, GA 
 (0.3 miles away)
404-778-0519
Experience:
41+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edmund Waller is a Hematologist Oncology provider practicing medicine in Atlanta, Georgia. He has been practicing medicine for over 41 years. Dr. Waller is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Graft Versus Host Disease (GvHD), Chronic Graft Versus Host Disease (cGvHD), Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), and Bone Marrow Transplant. Dr. Waller is board certified in American Board Of Internal Medicine, 1991.

Frequently Asked Questions about Dr. Ajay K. Nooka

How do I make an appointment with Dr. Ajay K. Nooka?

You can book an appointment with Dr. Ajay K. Nooka by calling their office at 404-778-0519. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ajay K. Nooka a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ajay K. Nooka is classified as an Elite expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ajay K. Nooka specialize in?

While Dr. Ajay K. Nooka is a Hematology Oncology, they have specific expertise in Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), and Smoldering Multiple Myeloma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology Oncology.

Does Dr. Ajay K. Nooka participate in research or clinical trials?

Yes. Dr. Ajay K. Nooka has published 194 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Dr. Ajay K. Nooka's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Ajay K. Nooka accept my insurance?

Dr. Ajay K. Nooka accepts most major insurance plans, including Aetna and Alliant Health. We recommend calling the office directly at 404-778-0519 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Nooka's expertise for a condition
ConditionClose
View All 59 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile